Dynavax Technologies (DVAX) Rating Increased to Hold at ValuEngine

Share on StockTwits

Dynavax Technologies (NASDAQ:DVAX) was upgraded by equities researchers at ValuEngine from a “sell” rating to a “hold” rating in a research note issued to investors on Thursday.

Other research analysts have also issued research reports about the stock. Cantor Fitzgerald reissued a “buy” rating and set a $30.00 price objective on shares of Dynavax Technologies in a research note on Monday, August 6th. Royal Bank of Canada lifted their price objective on shares of Dynavax Technologies to $26.00 and gave the stock an “outperform” rating in a research note on Monday, October 22nd. Zacks Investment Research raised shares of Dynavax Technologies from a “sell” rating to a “hold” rating in a research note on Thursday, August 9th. Cowen reissued a “buy” rating and set a $30.00 price objective on shares of Dynavax Technologies in a research note on Monday, October 22nd. Finally, BidaskClub lowered shares of Dynavax Technologies from a “sell” rating to a “strong sell” rating in a research note on Saturday, August 18th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and four have given a buy rating to the company’s stock. Dynavax Technologies has an average rating of “Hold” and an average price target of $28.00.

Shares of NASDAQ:DVAX opened at $12.09 on Thursday. Dynavax Technologies has a one year low of $9.63 and a one year high of $22.80. The company has a quick ratio of 8.67, a current ratio of 8.87 and a debt-to-equity ratio of 0.76. The company has a market cap of $756.69 million, a PE ratio of -6.99 and a beta of 0.61.

Dynavax Technologies (NASDAQ:DVAX) last issued its quarterly earnings results on Monday, November 5th. The biopharmaceutical company reported ($0.65) EPS for the quarter, missing the consensus estimate of ($0.57) by ($0.08). Dynavax Technologies had a negative return on equity of 87.67% and a negative net margin of 5,044.85%. The business had revenue of $1.46 million for the quarter, compared to analyst estimates of $3.16 million. During the same quarter in the prior year, the firm earned ($0.38) EPS. The firm’s quarterly revenue was up 2822.0% compared to the same quarter last year. As a group, equities research analysts forecast that Dynavax Technologies will post -2.49 earnings per share for the current fiscal year.

A number of institutional investors and hedge funds have recently made changes to their positions in the business. DekaBank Deutsche Girozentrale lifted its stake in Dynavax Technologies by 18.9% in the third quarter. DekaBank Deutsche Girozentrale now owns 402,000 shares of the biopharmaceutical company’s stock valued at $5,447,000 after buying an additional 64,000 shares in the last quarter. BlackRock Inc. lifted its stake in Dynavax Technologies by 1.4% in the third quarter. BlackRock Inc. now owns 4,123,662 shares of the biopharmaceutical company’s stock valued at $51,134,000 after buying an additional 56,568 shares in the last quarter. Lafayette Investments Inc. bought a new position in Dynavax Technologies in the third quarter valued at approximately $335,000. JPMorgan Chase & Co. lifted its stake in Dynavax Technologies by 1.8% in the third quarter. JPMorgan Chase & Co. now owns 264,669 shares of the biopharmaceutical company’s stock valued at $3,282,000 after buying an additional 4,591 shares in the last quarter. Finally, Falcon Point Capital LLC bought a new position in Dynavax Technologies in the third quarter valued at approximately $248,000. 81.48% of the stock is currently owned by hedge funds and other institutional investors.

About Dynavax Technologies

Dynavax Technologies Corporation, a biopharmaceutical company, focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor (TLR) stimulation. The company's lead product candidates include HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of the virus in adults age 18 years and older; SD-101, a cancer immunotherapy that is in Phase 2 clinical studies; and DV281, an investigational TLR9 agonist for the treatment of non-small cell lung cancer.

Recommended Story: What are earnings reports?

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Dynavax Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dynavax Technologies and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply